These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 22515841

  • 1. Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growth in vivo.
    Meier-Davis SR, Dines K, Arjmand FM, Hamlin R, Huang B, Wen J, Christianson C, Shudo J, Nagata T.
    Cutan Ocul Toxicol; 2012 Dec; 31(4):312-7. PubMed ID: 22515841
    [Abstract] [Full Text] [Related]

  • 2. Comparative single-dose pharmacokinetics of rasagiline in minipigs after oral dosing or transdermal administration via a newly developed patch.
    Lin Y, Zou Y, Lin J, Zhang T, Deng J.
    Xenobiotica; 2013 Aug; 43(8):705-10. PubMed ID: 23339547
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics, Pharmacodynamics, and Safety of a Single Escalating Dose and Repeated Doses of Rasagiline Transdermal Patch in Healthy Chinese Subjects.
    Wang M, Zhou W, Zhang Q, Zong S, Lv C.
    Clin Pharmacol Drug Dev; 2020 Jul; 9(5):602-609. PubMed ID: 31823527
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics, Pharmacodynamics, and Safety of Rasagiline Transdermal Patch: A Preliminary Study in Healthy Chinese Subjects.
    Zhou W, Lv C, Zhang Q, Zong S, Wang M.
    Clin Drug Investig; 2018 Feb; 38(2):125-133. PubMed ID: 29159774
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic interaction study between flavanones (hesperetin, naringenin) and rasagiline mesylate in wistar rats.
    Pingili R, Vemulapalli S, Mullapudi SS, Nuthakki S, Pendyala S, Kilaru N.
    Drug Dev Ind Pharm; 2016 Feb; 42(7):1110-7. PubMed ID: 26530401
    [Abstract] [Full Text] [Related]

  • 6. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR.
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [Abstract] [Full Text] [Related]

  • 7. Microemulsion-based gel for the transdermal delivery of rasagiline mesylate: In vitro and in vivo assessment for Parkinson's therapy.
    Patel P, Pol A, Kalaria D, Date AA, Kalia Y, Patravale V.
    Eur J Pharm Biopharm; 2021 Aug; 165():66-74. PubMed ID: 33971272
    [Abstract] [Full Text] [Related]

  • 8. Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice.
    Abi-Habib RJ, Singh R, Leppla SH, Greene JJ, Ding Y, Berghuis B, Duesbery NS, Frankel AE.
    Clin Cancer Res; 2006 Dec 15; 12(24):7437-43. PubMed ID: 17189417
    [Abstract] [Full Text] [Related]

  • 9. Nanoemulsion preparations of the anticancer drug dacarbazine significantly increase its efficacy in a xenograft mouse melanoma model.
    Tagne JB, Kakumanu S, Nicolosi RJ.
    Mol Pharm; 2008 Dec 15; 5(6):1055-63. PubMed ID: 19434855
    [Abstract] [Full Text] [Related]

  • 10. Oral administration of benzyl-isothiocyanate inhibits in vivo growth of subcutaneous xenograft tumors of human malignant melanoma A375.S2 cells.
    Ni WY, Hsiao YP, Hsu SC, Hsueh SC, Chang CH, Ji BC, Yang JS, Lu HF, Chung JG.
    In Vivo; 2013 Dec 15; 27(5):623-6. PubMed ID: 23988897
    [Abstract] [Full Text] [Related]

  • 11. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR.
    Clin Cancer Res; 1997 Nov 15; 3(11):2063-74. PubMed ID: 9815598
    [Abstract] [Full Text] [Related]

  • 12. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group.
    Arch Neurol; 2005 Feb 15; 62(2):241-8. PubMed ID: 15710852
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the cutaneous iontophoretic delivery of rasagiline and selegiline across porcine and human skin in vitro.
    Kalaria DR, Patel P, Patravale V, Kalia YN.
    Int J Pharm; 2012 Nov 15; 438(1-2):202-8. PubMed ID: 22954444
    [Abstract] [Full Text] [Related]

  • 14. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
    deMarcaida JA, Schwid SR, White WB, Blindauer K, Fahn S, Kieburtz K, Stern M, Shoulson I, Parkinson Study Group TEMPO, PRESTO Tyramine Substudy Investigators and Coordinators.
    Mov Disord; 2006 Oct 15; 21(10):1716-21. PubMed ID: 16856145
    [Abstract] [Full Text] [Related]

  • 15. Lack of clinically significant interactions between concomitantly administered rasagiline and escitalopram.
    Hilli J, Korhonen T, Laine K.
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov 13; 33(8):1526-32. PubMed ID: 19733607
    [Abstract] [Full Text] [Related]

  • 16. Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas.
    Hwang TL, Lee WR, Hua SC, Fang JY.
    J Dermatol Sci; 2007 Apr 13; 46(1):11-20. PubMed ID: 17267180
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.
    Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C.
    J Clin Pharmacol; 2007 Oct 13; 47(10):1256-67. PubMed ID: 17715422
    [Abstract] [Full Text] [Related]

  • 18. Impact of rasagiline nanoparticles on brain targeting efficiency via gellan gum based transdermal patch: A nanotheranostic perspective for Parkinsonism.
    Bali NR, Salve PS.
    Int J Biol Macromol; 2020 Dec 01; 164():1006-1024. PubMed ID: 32619667
    [Abstract] [Full Text] [Related]

  • 19. Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion.
    Bernacki RJ, Oberman EJ, Seweryniak KE, Atwood A, Bergeron RJ, Porter CW.
    Clin Cancer Res; 1995 Aug 01; 1(8):847-57. PubMed ID: 9816054
    [Abstract] [Full Text] [Related]

  • 20. A novel transport and delivery mechanism underpins the effectiveness of prolyl-m-sarcolysyl-p-fluorophenylalanine (PSF) in a human melanoma xenograft nude-mouse model.
    Dierickx KM, Morandini R, Nguyen TH, Salès F, Kauffmann JM, Ghanem GE.
    Pigment Cell Melanoma Res; 2008 Aug 01; 21(4):439-50. PubMed ID: 18627526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.